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Trends
Genome and exome sequencing are
revealing many candidate loss-of-func-
tion (knockout) variants in every human
genome.
Sequencing consanguineous popula-
tions is the most efﬁcient way of dis-
covering additional knockouts.
The phenotypic consequences of
apparent knockouts are difﬁcult to pre-
dict accurately because of (i) imperfect
variant calling, gene annotation, and
prediction of the molecular conse-
quences at the RNA and protein levels,
and (ii) variation in the biological con-
sequences of knocking out different
genes.
Human knockouts provide opportu-
nities to investigate gene function and
essentiality, as well as to suggest and
validate potential drug targets.
The clinical interpretation of knockouts
is complicated by all the above factors,
in addition to variable penetrance and a
lack of suitable databases.
Consistent calling, annotation, and
database standards for variants are
presently needed.
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Whole-genome and whole-exome sequence data from large numbers of individ-
uals reveal that we all carry many variants predicted to inactivate genes (knock-
outs). This discovery raises questions about the phenotypic consequences of
these knockouts and potentially allows us to study human gene function through
the investigation of homozygous loss-of-function carriers. Here, we discuss
strategies, recent results, and future prospects for large-scale human knockout
studies. We examine their relevance to studying gene function, population genet-
ics, and importantly, the implications for accurate clinical interpretations.
The Need to Understand Knockouts
Early in 2017, parents bring their newborn baby into Dr Wuhabi's clinic. There is nothing
obviously wrong, but the parents are worried. Dr Wuhabi has the baby's genome sequenced:
there are no variants from the actionable list, but a homozygous knockout of little-studied gene is
called. How should she advise the parents?
This scenario is imaginary, but may soon be reality. Knockouts of some genes in humans
certainly cause genetic diseases, but for other genes the consequences depend on the genetic
background or environment; yet other knockouts may have no detectable effect, or may even be
beneﬁcial. A ﬂurry of recent papers has begun to reveal not only the prevalence of knockouts in
the population, and their scientiﬁc interest, but also the complexity of understanding their
medical implications. We review here these new developments, the steps necessary for their
clinical interpretation (Figure 1, Key Figure), and consider possible future steps to resolve some
of these complexities.
Is It Really a Knockout?
While sequencing technology is becoming a ubiquitous part of genetic diagnosis, understand-
ing the impact of the variation discovered on the human phenotype remains a challenge, as
illustrated above. Naturally-occurring knockout or loss-of-function (LoF, see Glossary)
variants (the terms are interchangeable), in other words genetic variants that are predicted
to severely disrupt the function of human protein-coding genes [1], are often prime candidates
for follow-up. However, signiﬁcant difﬁculties remain: ﬁrst, with the identiﬁcation and calling of
DNA variants and, second, with the annotation of whether they truly disrupt protein function
or not (Figure 1). LoF variants as a class are rare (Figure 2) [2] and are poorly called by current
methods.  While exome sequencing and whole-genome sequencing technologies allow
reliable calling of SNPs, calling small insertions and deletions remains a developing area.
Moreover, differences in coverage as well as in an inability to span breakpoints decrease
sensitivity for calling large structural variants [3]; these non-SNP variants make up a large
fraction of naturally-occurring knockout variation and may still have high error rates. From a
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Glossary
Actionability of knockout
variation: the ability to use genotype
data to change clinical management
or therapy.
Annotation: the description of genes
and other elements in the genome as
well as their functions, including the
likely functional impact of variants [58].
Annovar: a tool to functionally
annotate genetic variants detected in
diverse genomes.
Bottleneck: a severe reduction in
size of a population, often short-term
and followed by an expansion.
Breakpoint: the location at which a
recombination event occurs between
two genomic locations or
chromosomes.
Calling of DNA variants: identifying
the nucleotide or structural
differences between a sequence of
interest and the reference sequence.
Consanguineous: a pedigree in
which the sampled individual has
parents sharing a recent common
ancestor.
Coverage: the number of sequence
reads covering a particular position in
the genome.
CRISPR/Cas9: bacterial clustered
regularly interspaced short palindromic
repeats (CRISPR) used with the Cas9
(CRISPR-associated) enzyme for
efﬁciently editing genetic material.
Exome sequencing: technique for
enriching and sequencing most or all
of the protein-coding gene segments
(exons) in a genome.
Fetal akinesia: term used to
describe a clinically and genetically
heterogeneous constellation of
conditions that exhibit growth
retardation and developmental
anomalies.
Gene damage index (GDI): a
process to score human genes based
on their accumulated mutational
damage, as assayed on the variation
from the 1000 Genomes Project and
their CADD scores (combined
annotated dependent depletion),
measuring deleteriousness of single-
nucleotide or insertion/deletion variants.
GENCODE: set of high-quality gene
reference annotations and their
experimental validation for human
and mouse genomes.
Gene-trap assay: a high-throughput
approach to introduce insertional
mutations into a mammalian genome.
Haploinsufﬁciency: the state in a
diploid organism where a single
functional copy of a gene (with theSanger sequencing or Sequenom genotyping) is always needed, and must be part of
standard practice [4].
Furthermore, when studying homozygous variants, the possibility of mosaic homozygous/
heterozygous status due to somatic crossover needs to be considered. Similarly, compound
heterozygous LoF variants in the same gene on different chromosomes knock out the gene,
while equivalent variants on the same chromosome only knock out a single copy. Further,
inconsistencies in gene reference sets and the annotation of protein-coding genes add an
additional layer of complexity. There can be considerable differences [5] between knockouts that
are called using different widely used gene models for human protein coding genes such as
RefSeq [6] and GENCODE [7]. In addition, software packages used to derive the consequen-
ces of sequence variation on proteins, such as Annovar [8] or Variant effect predictor (VEP)
[9], can produce further differences even when using the same gene models [10].
In addition to the subtleties in drawing up an initial list of knockout variants, predicting the effect
of a speciﬁc variant on protein production and on the phenotypic consequences of an observed
transcript reduction remain even more challenging. Transcript levels can readily be measured,
and are relevant because large deletions may remove a transcript entirely, while smaller LoF
variants may lead to nonsense-mediated decay (NMD) (Box 1) which reduces the transcript level.
Surprisingly, even if genetic variation triggers NMD and there is degradation of the RNA, the
reduction in RNA levels may not reduce the protein level [11]. Finally, the effect of alternative
splicing may lead to partial LoF variants, which affect only a subset of the transcripts of a gene,
meaning that a functional protein may still be produced from other transcripts. It is currently
effectively impossible to assess the relative functional importance of different transcripts for most
genes, and partial LoF variants can cause Mendelian disease [12]. To sidestep these
limitations, strategies which ﬁlter variants based on deterministic rules that best predict true
LoF behavior have been developed (LOFTEE: loss-of-function transcript effect estimator;
https://github.com/konradjk/loftee) but their systematic evaluation using large-scale RNA
and protein data is still incomplete. In settings where annotation is important for diagnosis,
further conﬁrmation of loss needs be obtained by direct observation of an absence of the protein
product or activity from a suitable sample. Only then can we be fully conﬁdent of a knockout.
Is it on the Disease-Causing List?
Many proteins are unnecessary for general life and good health: olfactory receptors, our largest
gene family, provide a prime example [13]. Thus, even for a conﬁrmed knockout, we still need to
determine whether it has a relevant phenotypic effect. The traditional way to do this is to look in a
list or database of known disease-causing variants. Decades of work by clinical geneticists and
physicians have led to the compilation of such databases. The predominant approach has been
to discover candidate causal genes/variants segregating in families and follow them by analyzing
additional patients with similar phenotypes. After assessing the mode of inheritance (dominant,
recessive, etc.), the presence of the same or equivalent variant (often LoF or a damaging amino
acid substitution) in the same gene, and its absence from a sample of unaffected individuals, has
been considered to establish causality. More recently, tools have been designed to enable
computational prediction of mutations (Box 2).
Beyond simple Mendelian conditions, this approach has also been successful in identifying
causal genes for more complex disorders by focusing on extreme and rare phenotypes. The ﬁrst
large-scale sequencing study performed in consanguineous families led to the identiﬁcation of
50 novel candidate genes for developmental disorders [14]. This success was soon followed by
the sequencing of an even larger cohort of 1113 trios and the implementation of a robust
translational genomics workﬂow to allow feedback of potentially diagnostic ﬁndings to clinicians
and research participants [15]. Importantly, by utilizing a genotype-driven approach to identify342 Trends in Molecular Medicine, April 2016, Vol. 22, No. 4
other copy inactivated by mutation)
does not produce enough of its
product (typically a protein) to lead to
the wild-type condition, generating an
abnormal or diseased state.
Identical-by-descent: portions of
the genome where the maternal and
paternal copies have identical
sequences owing to inheritance from
the same common ancestor.
Loss-of-function (LoF): variants
causing the reduction or complete
loss of a gene product, thereby
impairing its biochemical function.
Note that LoF variants are often only
predicted LoF variants.
Mendelian disease: a genetic
disease determined by a single locus,
exhibiting an inheritance pattern that
follows the laws of Mendel.
Mosaic: the presence of two or
more populations of cells with
different genotypes in one individual.
Penetrance: the chance that a
genotype results in particular
phenotype.
RefSeq: an annotated and curated
collection of publicly-available
nucleotide sequences (DNA, RNA)
and their protein products.
Residual variation intolerance
score (RVIS): a gene-based score
intended to rank genes in terms of
whether they have more or less
common functional genetic variation
relative to the genome wide
expectation given the amount of
apparently neutral variation the gene
has.
Sanger sequencing: a method of
DNA sequencing based on the
selective incorporation of chain-
terminating dideoxynucleotides by
DNA polymerase during in vitro DNA
replication, established by Fred
Sanger and often used for small-
scale genotype validation.
Sequenom genotyping: a method
of genotyping by extending
oligonucleotides with the single
nucleotide of interest followed by
determining the mass (and hence
nucleotide added) by mass
spectrometry, often used for
medium-scale genotype validation.
Single-molecule phasing: a
method for sequencing individual
long molecules of DNA and thus
identifying the set of variants that a
single molecule (and thus single
chromosome) carries (the phase of
these variants).
Somatic crossover: genetic
recombination (crossover) in somatic
cells (the soma), contrasted withsubsets of patients with similar disorders, the newly implicated genes increased by 10%
the proportion of subjects who received a diagnosis [16]. As such, exome sequencing of single
patients with extreme phenotypes has been applied more widely. For example, a knockout of the
immune gene IRF7 was shown to confer susceptibility to ﬂu viruses, leading to life-threatening
inﬂuenza in an otherwise healthy child [17].
In a similar vein, sequencing of fetuses lost preterm has identiﬁed novel knockout variants in
CHRNA1, a muscle acetylcholine receptor, as a cause of lethal fetal akinesia [18]. More
generally, family-based designs to uncover recessive forms of embryonic lethality by examining
signiﬁcant depletion of transmitted homozygote genotypes have implicated THSD1, a throm-
bospondin type 1 domain-containing protein of poorly understood function, as a candidate for a
monogenic cause of embryonic lethality [19]. Taken together, Mendelian disease genes and
embryonically lethal genes provide a spectrum of knockout variants ascertained as disease-
causing by analyzing carriers of clinically diagnosed phenotypes. Further sequencing in this
domain with larger sample sizes, better curation, and deeper phenotyping will steadily increase
this catalog. Moreover, a complementary approach is to sequence healthy people: the knock-
outs they carry are unlikely to be disease-causing. However, that interpretation of such lists is not
as simple as it seems.
How Can We Best Discover More Knockouts?
The logical end to the approach described above is to discover knockouts in all of the 20 000 or
so human protein-coding genes and classify them as either being lethal before birth, compatible
with life but disease-causing, or as having no disease consequences. However, LoF variants
typically have very low frequencies, meaning that very large sample sizes are required to
systematically discover LoFs in every gene. With the cost of sequencing decreasing, there
have been several approaches to uncover novel knockout variants on a large scale, using
different strategies.
A simple approach is to collect a large number of individuals from multiple cohorts that have
already been sequenced for diverse studies. The Exome Aggregation Consortium (ExAC)
has put together such a collection of >60 000 exomes from a wide range of phenotypes and
ages. This non-trivial exercise required performing reproducible variant calling and quality
control across the entire set of exomes that have been sequenced on different platforms and
time-periods [20]. At this scale, sequencing has been able to identify a variant in at least one
individual at one in every eight bases of coding sequence, as well as many sites with
recurrent mutations. This work has enabled us to understand the extent of haploinsufﬁ-
ciency in the genome with the observation that 3230 genes exist with a severe depletion of
heterozygous knockout variants, most of which do not have an established human disease
phenotype [21]. Given the large sample size of the data, it is also possible to investigate the
tolerance to dominant consequences of knockouts of individual genes by employing a
model that compares the synonymous mutational load with that of LoF mutations, taking
into account gene length and base composition [22]. For example, an excess of LoF
mutations in a particular novel gene for a disease cohort can indicate that certain mutations
are disease-causing [23].
While sequencing individuals without selecting for particular population-genetic properties is an
effective approach, such studies are in practice currently limited to the study of heterozygous
LoF variants [24]. In randomly-mating populations, a variant present in 1 in 1000 individuals in a
heterozygous state will only be present in 1 in 1 000 000 in a homozygous state, and discovering
homozygous mutations by sequencing outbred individuals will therefore require very large
sample sizes. Nevertheless, two complementary approaches have been used to discover rare
homozygous knockouts.Trends in Molecular Medicine, April 2016, Vol. 22, No. 4 343
recombination during meiosis in germ
cells.
Trios: three individuals, consisting of
a mother, a father, and their child.
Variant effect predictor (VEP): a
tool within ENSEMBL for the
functional annotation of variants.Bottlenecked populations with extensive identity-by-descent (identical-by-descent genomic
portions) present the most direct approach, and recently, 100 000 individuals from Iceland [25]
and 30 000 individuals from Finland [26] (two such bottlenecked populations) have now been
sequenced. Mildly pathogenic variants in small populations such as these are also more likely to
drift to higher frequencies than in large populations, and association studies aiming to ﬁnd
pathogenic variation have also discovered knockout variants that lead to chronic disease. A
striking example involved the identiﬁcation of a LoF variant leading to insulin resistance, with an
allele frequency of 17% in Greenland [27]. However, the potential of this strategy for discovering
homozygous knockouts is limited by two factors. First, the portion of the genome that is
identical-by-descent in these individuals, while higher than in outbred populations, is still small,
especially when education programs reduce marriage between close relatives [28]. Therefore,
the number of rare homozygous knockouts discovered per person is low. Second, the number
of knockouts present in the entire population is limited to those present in founders (plus new
mutations), and thus existing studies may already have discovered most of the LoF variation [26].Key Figure
Steps for the Clinical Interpretation of a Genetic Variant Discovered in a Genomic Sequence of
Interest
Exome or genome sequence
Variant callset
Annotated raw LoF variants
Conﬁdent  LoF variants
Rare LoF
Real homozygous LoF
Genotype-validated LoF
Funco nally validated LoF
Related clinical phenotype
Known
pathogenic LoF
Evi denc e in model
organisms or cell lines
Clinical acon neededClinically uncertain Likely not pathogenic
Heurisc rules
Allele frequency <1%
Common LoF
A real variant?
A real knockout?
Evidence for
disease causality?
Clinical interpretaon
Mosaicism check
Mosaic LoF
Genotype validaon
Genotype non-validated LoF
RNA/protein level
Funco nally no n-validated LoF
A unknown
pathogenic LoF
Evi denc e in model
organisms or cell lines
Starng data
Allele frequency >1%
Annotaon
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No
Figure 1. In increasing order of complexity, decisions must be made about whether or not (yes/no) (i) the variant itself is real, (ii) really leads to the knockout of the gene,
and (iii) there is evidence that it is likely to cause disease. As a result, the interpretation may be that clinical action is needed, that the variant is not likely to be pathogenic, or
that the clinical implications are uncertain. Abbreviation: LoF, loss of function.
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Figure 2. Allele Frequency Spectrum of Different Classes of Variants in the 1000 Genomes Project Data.
Alleles were assigned to a bin according to their frequency in the study population, and the bins plotted in order of increasing
frequency on the horizontal axis, with the functional classes being indicated by different colors within each bin. Singleton,
doubleton, or tripleton variants refer to those seen only once, twice, or three times in the data, respectively. In this sample
from apparently healthy populations, variants seen in disease databases such as ClinVar (ClinVar; dark red) are observed
almost exclusively in single individuals. Loss-of-function variants (LoF; orange), which knock out genes and represent the
most damaging functional class of variant, are also seen most often in only a single individual, although some are more
frequent. Non-synonymous variants (NonSyn; blue), which change an amino acid in the protein, are on average present at
higher frequency in the population, and are thus shifted towards the right-hand side of the plot. Synonymous variants (Syn;
grey), which do not change an amino acid, have on average the highest allele frequencies.This would mean that future sequencing of individuals from these cohorts is less likely to yield
novel mutations.
An alternative approach is to investigate consanguineous populations, which have high degrees
of parental relatedness, and large portions of their genome that are identical-by-descent
because of family structure in the immediate preceding generations. Two recent studies have
sequenced individuals of Pakistani descent and shown that one in every two individuals who are
the offspring of ﬁrst cousins has a rare knockout variant [29,30]. This rate is almost 50-fold higher
than that discovered in bottlenecked populations. Reassuringly, overlap of genes from the
datasets that have been produced using this approach suggests that rare LoF variants are often
not shared between populations and that the rate of discovery of knockouts from consanguin-
eous cohorts is sufﬁciently high to increase our understanding of homozygous knockouts
substantially (Figure 3).Box 1. Understanding Nonsense-Mediated Decay (NMD)
The NMD pathway is found in all eukaryotes; its main function is to degrade and eliminate mRNA molecules that contain
aberrant stop codons. This protects against the production of aberrant proteins which may be harmful. Despite years of
effort and the formulation of rules to predict when NMD will be triggered, predictions remain unreliable [59]. The recent
discovery of a protein that prevents mRNA degradation, PTBP1, is therefore of considerable interest. It has been reported
that, when bound near a stop codon, PTBP1 blocks the NMD protein UPF1 from binding to 30-untranslated regions
(UTRs). PTBP1 can thus mark natural stop codons and prevent their degradation, allowing NMD to act on transcripts with
premature stop codons and thus degrade aberrant mRNAs [60].
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Box 2. Computational Prediction of Phenotypic Consequence of Variation
Recently, several tools have been designed to predict phenotypic consequence for knockout variation, for example the
genome-wide annotation of variants (GWAVA) score, and the Combined Annotation-Dependent Depletion (CADD) score
[61,62], allowing novel variants to be assessed. These tools are primarily variant-driven and determine pathogenicity by
looking at sequence context, evolutionary constraint, and their impact on proteins. However, in vivo studies in model
organisms have shown that these methods have high false-positive rates [63]. Complementary methods that utilize gene-
level methods such as residual variation intolerance score (RVIS [64] and gene damage index (GDI) [65] have also
been used for this purpose, and recent work has investigated the utility of gene-level thresholds in improving predictivity
[66]. Furthermore, individual genes can be assessed together with others in close biological proximity to reﬁne their
phenotypic effect, as well as their susceptibility to disease, with network-based approaches such as the Human Gene
Connectome Map [67].How Can We Investigate the Phenotypic Consequences of Knockouts?
Although we have catalogs of knockout variants, and strategies for large-scale discovery of more
such variants, understanding the impact of gene knockouts, and thereby gene function, is
considerably more difﬁcult. Large cohorts with linked health records evaluating gross patient
phenotypic status have been examined in recent studies [24,29]. However, information on
particular knockouts or genes remains difﬁcult to extract because these knockouts are generally
extremely rare and may be seen only in a single individual. Because the ascertainment is based
on the genotype, recall and deep phenotyping are often required. Once a particular knockout is
identiﬁed, family-based designs can potentially be used to ascertain more individuals sharing the
same (heterozygous or homozygous) variant. An example of this strategy was demonstrated in10 20 30 40 50 60 70 80 90 100
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Figure 3. Number of Genes Carrying Homozygous Knockout Variants. The graph depicts such variants dis-
covered by sampling populations with different structures and plotted as a function of sample size. Sequencing of parentally
related individuals (green) provides discovery rates an order of magnitude higher than other strategies using outbred
individuals (blue) or bottlenecked populations (orange). This implies that sequencing more parentally related individuals is the
best future strategy.
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the discovery of a rare complete knockout in APOC3, which encodes an LDL protein, where a
single individual with extremely low fasting triglyceride levels from a remote village in Pakistan
was initially identiﬁed [29]. His extended family was later contacted and four more homozygous
knockout individuals from the large pedigree were found. This greatly improved the association
signal and provided evidence implicating APOC3 in the control of triglyceride levels in the blood
[29]. Similarly, a homozygous knockout variant of PRDM9 (PRDM9 directs and initiates recom-
bination in mammalian cells) was found in one woman from a cohort of 3222 individuals [30].
Follow-up by single-molecule phasing of her genome, together with that of her child, validated
the predicted altered recombination pattern, and thus revealed PRDM9 redundancy in humans
[30]. These discoveries illustrate the effectiveness of deep phenotyping of individual gene
knockouts discovered through population sequencing because these tie together patient,
epidemiological, molecular, and electronic health record data in the identiﬁcation of novel
biological functions for human genes.
Alternatively, cellular assays or model organisms can be used to provide evidence of variant
pathogenicity by showing that a knockout variant alters gene function with consequences that
mimic a disease phenotype, and that these differences are rescued by methods that recover the
wild-type function. This approach, together with the ability to generate knockout mutations
rapidly, has allowed the testing of synthetic lethality in human cell lines. In the past year, this has
been investigated at large using CRISPR/Cas9 and whole-genome gene-trap assays to
screen for genes required for proliferation and survival in near-haploid KBM7 chronic myeloge-
nous leukemia cell lines [31,32]. These studies have highlighted approximately 2000 genes
essential to human cellular function in these systems, which in fact parallel those found in yeast
[33]. Such analyses have allowed us to further understand the phenotypic consequences of
gene knockouts.
How Should We Interpret Knockouts in the Clinic?
The biggest challenge, however, lies in how we interpret the effect(s) of a variant on health-
related phenotypes because these are often moderated by other genetic variants or by the
environment. This variability in the resulting phenotype, known as incomplete penetrance [34],
makes the interpretation and actionability of knockout variation particularly challenging.
Several online databases exist to annotate the clinical relevance of genes or variants and the
effect of knockout variation on phenotype. The widely used databases Online Mendelian
Inheritance in Man (OMIM; http://omim.org/), The Human Gene Mutation Database (HGMD)
[35], and ClinVar [36] rely largely on cases reported in the literature, and LoF variants are major
components of their lists (Figure 4); but, as discussed above, these are generally ascertained
from affected individuals and their penetrance is often poorly understood. Moreover, some of the
reported disease genes and variants may only include evidence from a single individual or family.
However, sequencing-initiated population screens, which are mostly recruited from healthy
cohorts, present a contrasting ascertainment by detecting the variant independently of its
penetrance. Moreover, we are learning that incomplete penetrance may be the rule rather than
the exception. For example, knockouts in GJB2, which encodes a gap junction subunit
expressed in the developing cortex, and which cause hearing loss, have been widely studied
and accepted as a clear Mendelian condition with high penetrance; however, population
screens have revealed the existence of individuals harboring knockouts who exhibit normal
audiometry [30]. Another example involves a knockout variant in KMT2F, a gene which forms
part of a histone methyltransferase (HMT) complex that methylates histone H3 at Lys4. This
same variant has been implicated in a large case–control schizophrenia study, as well as in
probands with intellectual disability, thus making the diagnosis of the disease associated with the
genotype difﬁcult to determine [37]. Generally, when only phenotypic information about a few
individuals with a particular genotype is available, and the phenotypes differ, predicting phe-
notype from genotype may be virtually impossible.Trends in Molecular Medicine, April 2016, Vol. 22, No. 4 347
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Figure 4. Proportions of Different Variant Classes in the General Population. The graph provides data from the
1000 Genomes Project, Phase 3 (lower bar), and the ClinVar database of disease-associated variants (ClinVar; upper bar).
Non-synonymous variants (NonSyn; blue) are abundant in both samples; synonymous variants (Syn; grey) are abundant in
the general population, but seldom cause disease; LoF variants are scarce in the general population but form a high
proportion of ClinVar entries (LoF, orange). This shows that, although knockout variation is present at low frequency in the
general population, it has a substantial impact on disease.In light of these complexities, there is great need for consolidated approaches to sharing informa-
tion in a reproducible manner. Consolidated data should include information ranging from read
information and quality metrics of the sequence data to knockout allele frequencies in different
cohorts and health status of the carrier individuals. Crucially, as recent reviews on clinical action-
ability suggest [38–41], there is a need for scoring LoF variants, including those of the same gene,
on a quantitative scale from benign to pathogenic. It is essential for the information to be curated in
such a manner that crucial data, both in terms of observational phenotypes as well as quantitative
measurements, are aggregated into a framework [42]. The scoring schema should reﬂect study
design, gene and variant level data, publications and databases, as well as clinical diagnosis. This
would allow translation of genomic research ﬁndings into the clinical diagnostic setting and
empower informed decisions about actionability [42].
What Can We Learn about the Population Genetics of Knockouts?
Outside the medical domain, there is great interest in understanding the extent and impact of
LoF variants from a population-genetic perspective. The average number of LoFs per person
(100) in populations from Africa, Europe, and East Asia, and their characteristics of low allele
frequency and type (less than half of LoF variants are SNPs), were discovered by sequencing the
ﬁrst 150 individuals in the 1000 Genomes Project [43].
Further sequencing in control cohorts has provided a better understanding of the portion of the
genome that is essential [44], both in terms of genes that are haploinsufﬁcient as well as those
that are recessive. By examining the effects of purifying selection (Box 3), which removes
strongly deleterious LoF variants, we can identify a set of genes under evolutionary constraint.
These genes are also more likely to contribute to human disease [45]. We have also been able to
measure the effect of purifying selection directly; there is now a better estimate of lethal
equivalents or, rather, of the human mutational load of heterozygous mutations that would
be lethal if homozygous, from looking at (i) severe disease cases in founder populations [46], or (ii)348 Trends in Molecular Medicine, April 2016, Vol. 22, No. 4
Box 3. The Impact of Demography on the Efﬁcacy of Selection
In the past few years there has been much debate about the impact of demography on the efﬁcacy of selection because
allele frequency changes as a result of random genetic drift are expected to be greater in small populations, and thus
selection less effective. In human populations, genetic effective population sizes within Africa are generally larger than
outside, and so demographic impact on selection has therefore been evaluated by comparing populations within and
outside Africa [68–71]. The ability to detect selection in genetic sequence data depends on the selective coefﬁcient
(measuring how strong selection has been), the mode of action of the variant (dominant or recessive), and the time over
which selection has occurred. Inbred populations such as those sequenced to ascertain homozygous knockout variation
represent a signiﬁcant deviation from the demography of other human populations and can be used to measure this
effect. In this setting, substantial portions of the genome of each individual may be identical-by-descent, and thus all
variants in the population are often present in a homozygous state. Severely disadvantageous LoF variants, even if
recessive, therefore manifest their phenotype, and are removed by natural selection, perhaps even in a single generation.
This ‘purging through inbreeding’ leads to a lower number of LoF variants per individual than in an equivalent non-inbred
population [30]. While observed in closely related species, most strikingly in mountain gorillas which have had extreme
levels of inbreeding over long timescales [72], empirically observing this purging in humans has been difﬁcult, although is
expected to occur.consanguineous pedigrees with a deﬁcit in homozygous genotypes [30]. These studies have
determined that any human individual carries, on average, between one and two recessive lethal
variant equivalents per genome.
How Are Knockouts Useful?
Perhaps the study of gene knockouts is most useful when examining instances where a
naturally-occurring LoF variant proves beneﬁcial to health. Notable examples include lowering
LDL levels (PCSK9), decreasing susceptibility to HIV (CCR5), increasing endurance (ACTN3) and
increasing sepsis resistance (CASP12) [47–49]. These discoveries have not only stimulated drug
development but have also prompted further genetic testing of these genes; for instance,
additional modifying alleles of CCR5, linked to HIV susceptibility, were identiﬁed in African
populations [50].
Drug safety checks are a crucial component of the clinical trial process, and the majority of
compounds that enter trials fail to demonstrate safe use and are then abandoned, often after
considerable expense. Naturally-occurring variants in humans affecting the activity or dosage of
a particular gene or protein can be used in effective drug screens before embarking on clinical
trials, serving in the determination of drug toxicity parameters [51]. This approach is exempliﬁed
by lipid genes, where longstanding cohort studies have shown the beneﬁts of lowering choles-
terol levels. For example, in addition to the PCSK9 knockouts mentioned above, APOC3
knockouts have been assessed – APOC3 deﬁciency has been shown to lead to reduced
triglyceride levels in humans [52]. In both cases, humans with knockouts live long healthy lives,
strongly suggesting that drug-mediated reductions in protein levels should be safe [53].
Importantly, genetics can also inform drug efﬁcacy when the phenotype of heterozygous
and homozygous knockouts can mimic dose–response curves. For example, the drug dar-
apalib, aimed at treating atherosclerosis [54], failed to pass drug trials, exemplifying a case where
large-scale clinical trials across tens of thousands of people could have been avoided if only the
genetic screen showing a lack of molecular phenotype could have been ﬁrst examined.
Another important use of knockouts involves the identiﬁcation of modiﬁer genes via variation in
penetrance. In one application of this principle, the genomes of individuals carrying knockouts
without the expected disease phenotype can be searched for naturally-occurring compensatory
or modifying variants. Such studies have, for example, revealed secondary variants in fetal globin
genes that modify the severity of sickle cell disease by ameliorating the effect of the primary
causal variant in the b-globin gene [55]. A study studying symptom-free adults is now under way
to systematically search for such ‘resilience’ variants modifying early-onset childhood disorders
in a set of diseases known to have a single monogenic cause [56,57].Trends in Molecular Medicine, April 2016, Vol. 22, No. 4 349
Outstanding Questions
When does a candidate knockout vari-
ant identiﬁed in a DNA sequence result
in absence of the protein product?
When and how does the full knockout
of a protein product inﬂuence the phe-
notype of the carrier?
How many human gene knockouts are
(i) lethal before birth, and thus are never
observed; (ii) invariably or usually dis-
ease-causing; (iii) neutral, with only
subtle effects on the phenotype; or
(iv) beneﬁcial to the carrier?
How much do the consequences (i–iv)
vary between individuals, and how
does this depend on the genotype
background, environment, or other
factors?
What are the best ways to standardize
knockout identiﬁcation, annotation,
and database structure to support
accurate clinical interpretations?
Could general drug-based approaches
to reversing knockouts (e.g., read-
through of premature stop codons)
be effective?Concluding Remarks
Research on human gene knockouts, as well as on their phenotypic and clinical interpretation, is
very active. It is leading to the identiﬁcation of an increasing number of variants and, conse-
quently, the need for eliciting clinical action or not is becoming clear, even if many questions
remain in the ﬁeld (see Outstanding Questions). Noteworthy is the fact that, with a population size
of seven billion people worldwide, multiple knockouts of every human gene will have arisen from
new mutations in the last generation of conceptions. Fortunately, we now have the technologies
to continue analyzing and understanding such genetic mutations.
After checking the validation data for the gene knocked out in the baby, Dr Wuhabi looks it up in
the new online OKOD (Online KnockOut Database). There are two entries: an English woman
aged 55 years homozygous for a premature stop codon recorded as having two children, with
medical details ‘to be added’, and a Chinese man aged 92 years heterozygous for a deletion and
a splice-site variant in separate copies of the gene, recorded only with age-related hearing loss.
Dr Wuhabi reassures the parents that knockout of this gene is associated with normal life, and
that the genome sequence gives her no cause for concern.
This imaginary scenario is less plausible than our introductory one. Nevertheless, an increasing
community of patients, healthy volunteers, medical and scientiﬁc professionals, as well as
funders, could make this happen.
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